Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases
HemaSphere · 2026-06 · 10 (6)
DOI: 10.1002/hem3.70389 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 16.06.2026. Verfasst von Alexander Carpinteiro und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation West German Cancer Center, University Hospital Essen Essen Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Systemic light chain (AL) amyloidosis is a rare, acquired protein misfolding disorder characterized by extracellular deposition of misfolded immunoglobulin light chain fibrils, resulting in organ damage. Treatment is based on anti‐plasma cell regimens derived from multiple myeloma therapy. To date, no approved regimens exist for relapsed/refractory cases. This retrospective multicenter study, performed at 11 centers across Germany, evaluated the efficacy and tolerability of the treatment with teclistamab in 52 patients with relapsed/refractory AL amyloidosis. Hematologic response (≥very good partial response [VGPR]) was achieved in 81% of patients at Day 15, which increased to 95% at 3 months. Flow‐minimal residual disease (MRD) was negative in 96% (23/24) of cases. Cardiac and renal responses (≥partial response [PR]) at 6 months were 65% and 78%, respectively. Cytokine release syndrome occurred in 37% of cases, with two classified as Grade 3 and none as Grade 4. Neutropenia Grade 3 or 4 occurred in 5/52 (10%) of patients. The 1‐year overall survival was 83%, and the median overall survival was not reached after a median follow‐up time of 8.8 months. Factors including difference between involved and non‐involved free light chains (dFLC) ≥ 180 mg/L, N‐terminal pro‐brain natriuretic peptide (NTproBNP) ≥ 8500 pg/mL, glomerular filtration rate (GFR) < 20 mL/min/1.73 m 2 , and dialysis did not significantly impact overall survival. In total, nine patients deceased, six of whom deceased due to bacterial infections. Patients receiving immunoglobulin replacement therapy had a 2.01 lower risk of infections Grade 3 or 4 and a 6.14 lower risk of death. Our findings demonstrate the efficacy of teclistamab in a heavily diseased and pretreated cohort with AL amyloidosis and highlight the necessity of a concomitant immunoglobulin replacement therapy.
Autor:innen und Institutionen
- Department of Hematology and Stem Cell Transplantation West German Cancer Center, University Hospital Essen Essen Germany.
- Institute of Molecular Biology University of Duisburg-Essen Essen Germany.
- West German Amyloidosis Center University Hospital Essen Essen Germany.
- Department of Oncology and Hematology Klinikum Oldenburg, University Clinic Oldenburg Germany.
- Department of Internal Medicine V, Amyloidosis Center Heidelberg University Hospital Heidelberg Heidelberg Germany.
- Onkologicum HOPA Hamburg Germany.
ORCID-Profile: Alexander Carpinteiro, Evgenii Shumilov, Maximilian Steinhardt
Zitieren
APA
Carpinteiro, A., Kimmich, C., Trajanova, D., Hegenbart, U., Hansen, T., Holtick, U., von Landenberg-Roberg, V., Bohl, S. R., Teipel, R., von Metzler, I., Engelhardt, M., Shumilov, E., Steinhardt, M., Reinhardt, H. C., Oubari, S., & Schönland, S. (2026). Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. HemaSphere, 10(6). https://doi.org/10.1002/hem3.70389
Vancouver
Carpinteiro A, Kimmich C, Trajanova D, Hegenbart U, Hansen T, Holtick U, et al. Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. HemaSphere. 2026;10(6). doi:10.1002/hem3.70389
BibTeX
@article{Carpinteiro2026,
author = {Carpinteiro, Alexander and Kimmich, Christoph and Trajanova, Despina and Hegenbart, Ute and Hansen, Timon and Holtick, Udo and von Landenberg-Roberg, Vera and Bohl, Stephan Rainer and Teipel, Raphael and von Metzler, Ivana and Engelhardt, Monika and Shumilov, Evgenii and Steinhardt, Maximilian and Reinhardt, Hans Christian and Oubari, Sara and Schönland, Stefan},
title = {Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {6},
doi = {10.1002/hem3.70389}
}
EUVIMED